{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-102353","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.615419+00:00","generated_at":"2026-05-17T20:48:06.173903+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEAYA Q2 net loss $77.5M; cash ~$992M; darovasertib PFS data on track for YE2025","bullets":["Net loss of $77.5M for Q2 2025 vs $72.2M in Q1 2025; R&D expenses $74.2M, G&A $14.6M.","Cash, cash equivalents and marketable securities ~$992M as of June 30, 2025, down from $1.05B at March 31, 2025.","Darovasertib/crizotinib Phase 2/3 trial in 1L HLA-A2-negative MUM enrolled over 350 patients; median PFS data on track for YE2025 to potentially enable accelerated approval filing.","Three IND submissions by YE2025: IDE892 (PRMT5), IDE034 (B7H3/PTK7 bispecific ADC), IDE574 (KAT6/7).","IDEAYA to host R&D Day on Sept 8, 2025, with multiple clinical data updates including neoadjuvant darovasertib and IDE397 combo data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-102353","json":"https://secwatch.observer/filing/0000950170-25-102353.json","markdown":"https://secwatch.observer/filing/0000950170-25-102353.md","text":"https://secwatch.observer/filing/0000950170-25-102353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017025102353/0000950170-25-102353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017025102353/idya-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:48:06.173903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}